Regeneron (REGN) Tops Q4 EPS by 58c

Regeneron (NASDAQ: REGN) reported Q4 EPS of $7.50, $0.58 better than the analyst estimate of $6.92. Revenue for the quarter came in at $2.17 billion versus the consensus estimate of $2.11 billion.

• The Company and Sanofi announced intent to restructure antibody collaboration for Kevzara and Praluent

2020 Financial Guidance

Given the announcement regarding the intent to restructure the antibody collaboration for Kevzara and Praluent with Sanofi, Regeneron will provide financial guidance for full year 2020 by the end of the first quarter of 2020.

For earnings history and earnings-related data on Regeneron (REGN) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery